FDA approves Roche ’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 20 March 2019Source: European Journal of Surgical OncologyAuthor(s): Matthieu Siebert, Mohammad Alyami, Frederic Mercier, Colin Gallice, Laurent Villeneuve, Nathalie Laplace, Guillaume Passot, Naoual Bakrin, Olivier Glehen, Vahan KepenekianAbstractIntroductionPressurized intraperitoneal aerosol chemotherapy (PIPAC) is a promising technic for unresectable peritoneal metastasis (PM). Targeted therapies such as bevacizumab have demonstrated their efficacy in advanced colorectal and ovarian cancer. We aimed to evaluate the feasibility and safety of this bidimensional therapeutic association.M...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Authors: Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE, Choi EK Abstract OBJECTIVE: Somatic TP53 mutation (TP53mut) is a characteristic finding in high-grade serous ovarian cancer (HGSOC). The aim of this study was to assess the clinical efficacy and utility of TP53mut circulating tumor DNA (ctDNA) monitoring as a biomarker for managing HGSOC. METHODS: TP53muts were evaluated in patients who received primary treatment for suspected ovarian cancer at Asan Medical Center. In patients diagnosed with HGSOC and with TP53mut, ctDNA, cancer antigen 125 (CA 125), and computed tomography were followed up according to the treat...
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
AbstractAs a drug class, inhibitors of poly-(ADP-ribose) polymerase (PARP) have had their greatest impact on the treatment of women with epithelial ovarian cancers (EOC), in particular, those with the most common histological subtype, high-grade serous cancer, as it has high rates of homologous recombination (HR) deficiency. PARP inhibition exploits this cancer vulnerability by further disrupting DNA repair, thus leading to genomic catastrophe. Early clinical data demonstrated the effectiveness of PARP inhibition in women with recurrent EOC harbouringBRCA1/2 mutations and those with platinum-sensitive recurrences. Three PA...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
(MedPage Today) -- Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone
Source: MedPage Today OB/GYN - Category: OBGYN Source Type: news
Abstract Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential drawbacks of chemotherapy use of particular concern for newly diagnosed premenopausal breast cancer patients. Temporary ovarian suppression obtained pharmacologically with the administration of a gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy has been specifically developed as a method to counteract chemotherapy-induced gonadotoxicity with the main goal of diminishing the risk of POI. In recent years, important clinical evidence has become available on the efficacy and safety of this strategy that should...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: Clin Med Insights Reprod Health Source Type: research
The phase II trial evaluated  dendritic cell–based immunotherapy with concomitant administration of chemotherapy vs chemotherapy alone.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Volume 47, Issue 1, December 2019, Page 957-967 .
Source: Artificial Cells, Blood Substitutes, and Biotechnology - Category: Biotechnology Authors: Source Type: research
Publication date: Available online 15 March 2019Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): V. Lavoue, C. Huchon, C. Akladios, P. Alfonsi, N. Bakrin, M. Ballester, S. Bendifallah, P.A. Bolze, F. Bonnet, C. Bourgin, N. Chabbert-Buffet, P. Collinet, B. Courbiere, T. De la motte rouge, M. Devouassoux-Shisheboran, C. Falandry, G. Ferron, L. Fournier, L. Gladieff, F. GolfierAbstractAn MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (Grade A). In presumed early-stage ovarian or tubal cancers, ...
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
In conclusion, although functioning stromal cells of ovarian cancer are usually thought to be non-neoplastic, some may share an origin with carcinoma cells. PMID: 30867798 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
We examined the effect of catechin and cisplatin on human ovarian cancer cells’ SKOV-3 viability. It was also studied whether preincubation with catechin modulates drug resistance revealed by SKOV-3 cells. Catechin at concentratio ns up to 200 µM has been shown to be slightly toxic to the tested cells. Analysis of cells after preincubation with catechin revealed increased cytotoxicity of cisplatin compared to the cells treated only with cytostatic and changed expression of MDR-related proteins. Pre-treatment with catechin enhanced cisplatin cytotoxicity by promoting apoptosis and changing activity of mem...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Ovarian Cancer | Ovaries | Pharmaceuticals | Women